Compare Halliburton Company (HAL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs 10X Genomics Inc — how do they compare? Halliburton Company trades at $33.8 (market cap $29.33B), while 10X Genomics Inc trades at $42.79 (market cap $5.48B). The key difference: Halliburton Company is far larger — about 5.4× 10X Genomics Inc's market cap, and Halliburton Company pays a 1.94% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| HAL | TXG | |
|---|---|---|
Market Cap | $29.33B | $5.48B |
Sector | Energy | Health |
52-Week High | $42.98 | $45.80 |
52-Week Low | $20.50 | $11.34 |
Enterprise Value | $35.41B | $5.02B |
Dividend Yield | 1.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $35.56, up 0.97% on the day, with a bullish technical signal supported by moving averages. The company shows solid fundamentals with a P/E of 19.46 and ROE of 14.56%, though net income declined to $1.28B in 2025. Recent contract wins with Aramco in Saudi Arabia and TotalEnergies in Suriname highlight growth opportunities, while analyst consensus is strongly bullish with a $44.78 price target.
Outlook remains positive due to strategic contracts and oil price support from geopolitical tensions, but risks include Middle East volatility and cost pressures. The stock offers value with earnings beats and institutional backing, though investors should monitor debt levels and execution on new projects.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
